Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-03 · accession 0000950170-25-014808 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-05 | 2025-02-03 | TNGX | Barry Douglas | GC | A - Grant | $0.00 | +27.4K | 71.3K | +62% | $0 |
| D | 2025-02-05 | 2025-02-03 | TNGX | Barry Douglas | GC | A - Grant | $0.00 | +164.2K | 164.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | A | A | 27,363 | $0.00 | 71,344 | D | — | — | (F1) These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-03 | A | A | 164,175 | $0.00 | 164,175 | D | $2.91 · — to 2035-02-03 | 164,175 Common Stock | (F2) This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter. |